Ultragenyx CEO: Committed to helping patients pay for drugs

5:41 PM ET Tue, 8 April 2014

Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.